GLIMEPIRIDE 2mg. IP + METFORMIN 500mg. IP + VOGLIBOSE 0.2mg. IP

An antihyperglycemic medicine that is used to treat high blood sugar levels caused by type 2 diabetes. Stimulates pancreatic β cells to release insulin in patients with type 2 diabetes mellitus. (Abdul Basit, 2012) An effective and well-tolerated agent in a wide range of Type 2 diabetic Mellitus patients. (Ajay S. Dabhi, 2013) Delays the digestion and absorption of carbohydrates and inhibits postprandial hyperglycemia and hyperinsulinemia. (Xiaolong Chen, 2006) Prevents severe complications of diabetes such as diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy. An effective drug reduces fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels. (Abdul Basit, 2012) A beneficial and cost-effective treatment option for managing type 2 diabetes mellitus. (Abdul Basit, 2012) A well-tolerated agent that is effective in controlling both fasting and post-prandial glucose levels. (A.Faruqui, 2016) A good option in the management of type 2 diabetes which controlling both fasting as well as post prandial blood glucose and ultimately HbA1c values. (A.Faruqui, 2016) A safe and effective in the management of type 2 diabetes uncontrolled with dual therapy. (Hari K, 2014) Shows a significant benefit in controlling the glucose triad levels (HbA1C, fasting plasma glucose, and postprandial glucose level) when compared to dual therapy [glimepiride and metformin] in type 2 diabetic patients. (Krishna Murti, 2016)